You know those ads on late-night radio or in the back of some magazines for testosterone replacement therapy? Hate to be the bearer of bad news, but for older men that’s no real path to a male fountain of youth.
Like it or not, low testosterone is a normal part of aging and “fixing” it can be risky. Despite some news reports on the benefits of testosterone replacement therapy, several recent studies show that the harms may outweigh benefits. Continue reading
A mainstay of health reporting is covering outbreaks of foodborne illness, whether it’s salmonella in peanut butter (and its criminal consequences) or listeria in cantaloupes or ice cream. While the Centers for Disease Control and Prevention maintains a robust site documenting food-borne illness outbreaks, by the time the CDC cites a case on its website, the outbreak often already been in the news since potential outbreaks are first investigated by local and state health departments.
How do these smaller agencies decide how and when to publicize details about a suspected or confirmed outbreak? Continue reading
Journalists are in love with reporting new findings about a disease and a particular risk factor, but they are not so keen on following what happens later and reporting on whether the finding was replicated – and just over half the time is later disproved.
This comes from a recent study in PLOS ONE by authors who previously found that journalists tend to favor initial findings over subsequent findings on the same outcome. Continue reading
I’m frequently asked on social media for my thoughts on a particular study. In this situation, I thought the quick analysis I did may be instructive for others, so I’ve Storified it here, along with additional commentary and resources. Continue reading
Some of the most difficult research to make sense of comes from nutrition science. It is difficult, expensive and labor-intensive to conduct randomized controlled trials in nutrition, in part because they require randomizing what people eat and then ensuring they eat what they’re supposed to – no more and no less.
Even when such trials are finished (often at in-patient labs), the populations are usually small and somewhat homogenous, thus reducing the generalizability and overall clinical utility of results. Continue reading